Previous Article | Next Article ![]()
Journal of Virology, October 2001, p. 9142-9155, Vol. 75, No. 19
Department of Cancer Biology, Dana-Farber
Cancer Institute and Harvard Medical School, Boston, Massachusetts
02115
Received 11 April 2001/Accepted 2 July 2001
Simian virus 40 small t antigen (st) is required for optimal
transformation and replication properties of the virus. We find that in
certain cell types, such as the human osteosarcoma cell line U2OS, st
is capable of inducing apoptosis, as evidenced by a fragmented nuclear
morphology and positive terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling staining of transfected cells. The cell death
can be p53 independent, since it also occurs in p53-deficient H1299
cells. Genetic analysis indicates that two specific mutants affect
apoptosis induction. One of these (C103S) has been frequently used as a
PP2A binding mutant. The second mutant (TR4) lacks the final four amino
acids of st, which have been reported to be unimportant for PP2A
binding in vitro. However, TR4 unexpectedly fails to bind PP2A in vivo.
Furthermore, a long-term colony assay reveals a potent colony
inhibition upon st expression, and the behavior of st mutants in this
assay reflects the relative frequency of nuclear fragmentation observed
in transfections using the same mutants. Notably, either Bcl-2
coexpression or broad caspase inhibitor treatment could restore normal
nuclear morphology. Finally, fluorescence-activated cell sorting
analysis suggests a correlation between the ability of st to modulate
cell cycle progression and apoptosis. Taken together, these
observations underscore that st does not always promote proliferation
but may, depending on conditions and cell type, effect a cell death response.
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.19.9142-9155.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Induction of p53-Independent Apoptosis by
Simian Virus 40 Small t Antigen
and
*
Corresponding author. Mailing address: Department of
Cancer Biology, Dana-Farber Cancer Institute and Harvard Medical
School, 1 Jimmy Fund Way, Boston, MA 02115. Phone: (617) 632-3049. Fax: (617) 632-4770. E-mail:
thomas_roberts{at}dfci.harvard.edu.
Present address: Vertex Pharmaceuticals Inc., Cambridge, MA 02139.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»